{
    "root": "a5511d66-5602-4b66-88ad-66b4532fdfe1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Risperidone",
    "value": "20230915",
    "ingredients": [
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "Risperidone",
            "code": "L6UH7ZF8HC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3311"
        },
        {
            "name": "CALCIUM SULFATE, UNSPECIFIED FORM",
            "code": "WAT0DDB505",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31346"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        }
    ],
    "indications": {
        "text": "risperidone atypical antipsychotic indicated : \u2022 treatment schizophrenia ( 1.1 ) \u2022 monotherapy adjunctive therapy lithium valproate , treatment acute manic mixed episodes associated bipolar disorder ( 1.2 ) \u2022 treatment irritability associated autistic disorder ( 1.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "table 1. recommended daily indication initial dose titration ( increments ) target dose effective dose range schizophrenia : adults ( 2.1 ) 2 mg 1 2 mg 4 8 mg 4 16 mg schizophrenia : adolescents ( 2.2 ) 0.5 mg 0.5 1 mg 3 mg 1 6 mg bipolar mania : adults ( 2.2 ) 2 3 mg 1 mg 1 6 mg 1 6 mg bipolar mania : children adolescents ( 2.2 ) 0.5 mg 0.5 1 mg 1 2.5 mg 1 6 mg irritability autistic disorder ( 2.3 ) 0.25 mgcan increase to0.5 mg day 4 : ( body weight less 20 kg ) 0.5 mgcan increase to1 mg day 4 : ( body weight greater equal 20 kg ) day 4 , intervals > 2 weeks:0.25 mg ( body weight less 20 kg ) 0.5 mg ( body weight greater equal 20 kg ) 0.5 mg : ( body weight less 20 kg ) 1 mg : ( body weight greater equal 20 kg ) 0.5 3 mg severe renal hepatic impairment adults : lower starting dose 0.5 mg twice daily . may increase dosages 1.5 mg twice daily intervals one week longer .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal hepatic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_42738"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "risperidone contraindicated patients known hypersensitivity either risperidone paliperidone , excipients risperidone formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Risperidone is an atypical antipsychotic indicated for: \u2022 Treatment of schizophrenia ( 1.1 ) \u2022 As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) \u2022 Treatment of irritability associated with autistic disorder ( 1.3 )",
    "contraindications_original": "Table 1. Recommended Daily Dosage by Indication\n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              Initial Dose\n                           \n                           \n                              Titration\n                              \n                              (Increments)\n                           \n                           \n                              Target Dose\n                           \n                           \n                              Effective Dose Range\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 Schizophrenia: adults (2.1)\n                                 \n                              \n                           \n                           \n                              2 mg\n                           \n                           \n                              1 to 2 mg\n                           \n                           \n                              4 to 8 mg\n                           \n                           \n                              4 to 16 mg\n                           \n                        \n                        \n                           \n                              \n                                 Schizophrenia: adolescents (2.2)\n                                 \n                              \n                           \n                           \n                              0.5 mg\n                           \n                           \n                              0.5 to 1 mg\n                           \n                           \n                              3 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                        \n                        \n                           \n                              \n                                 Bipolar mania: adults (2.2)\n                                 \n                              \n                           \n                           \n                              2 to 3 mg\n                           \n                           \n                              1 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                        \n                        \n                           \n                              \n                                 Bipolar mania: children and\n                                 \n                                 adolescents (2.2)\n                                 \n                              \n                           \n                           \n                              0.5 mg\n                           \n                           \n                              0.5 to 1 mg\n                           \n                           \n                              1 to 2.5 mg\n                           \n                           \n                              1 to 6 mg\n                           \n                        \n                        \n                           \n                              \n                                 Irritability in autistic disorder (2.3)\n                                 \n                              \n                           \n                           \n                              0.25 mgCan increase to0.5 mg by Day 4:(body weight less than 20 kg)\n                                 0.5 mgCan increase to1 mg by Day 4:(body weight greater than or equal to 20 kg)\n                           \n                           \n                              After Day 4, at intervals of > 2 weeks:0.25 mg(body weight less than 20 kg)\n                                 0.5 mg(body weight greater than or equal to 20 kg)\n                           \n                           \n                              0.5 mg:(body weight less than 20 kg)\n                                 1 mg:(body weight greater than or equal to 20 kg)\n                           \n                           \n                              0.5 to 3 mg\n                           \n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "adverseReactions_original": "Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.",
    "drug": [
        {
            "name": "Risperidone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        }
    ]
}